Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.

Authors :: Senapati J
Abuasab T
Haddad FG
Ravandi F
Kadia T
DiNardo C
Daver N
Pemmaraju N
Alvarado Y
Brandt MA
Kantarjian H
Borthakur G
Source :: American journal of hematology [Am J Hematol] 2023 Mar; Vol. 98 (3), pp. E53-E56. Date of Electronic Publication: 2022 Dec 24.
Publication Year :: 2023

Subjects :: Humans
Granulocyte Colony-Stimulating Factor therapeutic use
Vidarabine therapeutic use
Mutation
Core Binding Factors
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Cytarabine therapeutic use
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics

Full Text Access

Tools